logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10028911 B1

PDFFull Text
Date of Patent:
Jul. 24, 2018

Filed:

Mar. 05, 2013

Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent

Applicant:

Pacira Pharmaceuticals, Inc., San Diego, CA (US);

Inventors:

Louie Daniel Garcia, San Diego, CA (US);

Lois Gibson, Bradley Beach, CA (US);

William Joseph Lambert, North Potomac, MD (US);

Benjamin W. Li, San Diego, CA (US);

Liangjin Zhu, San Diego, CA (US);

Assignee:

Pacira Pharmaceuticals, Inc., San Diego, CA (US);

Attorney:

Knobbe Martens Olson & Bear LLP

Primary Examiner:

Gollamudi Kishore

Int. Cl.
CPC ...
A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 31/198 (2006.01); A61K 31/25 (2006.01); A61K 31/519 (2006.01); A61K 31/575 (2006.01); A61K 31/685 (2006.01);
U.S. Cl.
CPC ...
A61K 9/127 (2013.01); A61K 9/0019 (2013.01); A61K 31/198 (2013.01); A61K 31/25 (2013.01); A61K 31/519 (2013.01); A61K 31/575 (2013.01); A61K 31/685 (2013.01);
Abstract

Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cof MTX between 5% and 50% of the Cof an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.

Find Patent Forward Citations

Garcia, Louie. (2018). Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent (U.S. Patent No. 10028911). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10028911

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…